

Author	Abstract Title	Presentation Type	Date & Time of Presentation
MIRCERA Presentations			
Authors: I.C. Macdougall, R. Walker, R. Provenzano, F. de Alvaro, H.R. Locay, P.C. Nader, F. Locatelli, F.C. Dougherty	C.E.R.A. (Continuous Erythropoietin Receptor Activator) Administered at Extended Intervals Corrects Hb Levels in Patients with CKD not on Dialysis	Poster	November 18 10:00 – 12:00 Hall C
Authors: M. Klinger, M. Arias, V. Vargemezis, A. Besarab, W. Sulowicz, T. Gerntholtz, K. Ciechaanowski, F.C. Dougherty	C.E.R.A. (Continuous Erythropoietin Receptor Activator) Administered at Extended Intervals Corrects Hb levels in Patients with CKD on dialysis	Poster	November 18 10:00 – 12:00 Hall C
Authors: N.W. Levin, E. Imbasciati, C. Combe, M.V. Rocco, C.E. Lok, S.M. Donnelly, F.C. Dougherty	Adequate Hb levels are Maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) Administered up to Once Monthly in Patients with CKD on Dialysis Irrespective of Age, Gender or Diabetic Status	Poster	November 18 10:00 – 12:00 Hall C
Authors: S. Fishbane, N.W. Levin, J.F.E. Mann, J.L. Lewis, M. Bernado, N.M. Lunde, F.C. Dougherty	IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) Once Every 2 Weeks or Once Monthly Maintains Stable Hb Levels after Converting Directly from IV Epoetin 1-3 Times per Week in Patients with CKD on Dialysis	Poster	November 18 10:00 – 12:00 Hall C
Authors: J-P. Ryckelynck, K. Harris, R. Selgas, T. Stompor, E. Ladanyi, S. Opatrna, F.C. Dougherty	SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) Administered up to Once Monthly in Patients with CKD on Dialysis Maintains Adequate Hb Levels Regardless of Age, Gender or Diabetic Status	Poster	November 18 10:00 – 12:00 Hall C
Authors: F. Locatelli, W. Sulowicz, K. Harris, R. Selgas, J. Kaufman, M. Klinger, F. Malberi, F.C. Dougherty	SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) Once Every 2 Weeks or Once Monthly Maintains Stable Hb Levels after Converting Directly from SC Epoetin 1-3 Times per Week in Patients with CKD on Dialysis	Poster	November 18 10:00 – 12:00 Hall C
Authors: M. Jarsch, M. Brandt, M. Kubbies, M. Lanzendörfer, A. Haselbeck,	C.E.R.A. Acts Differently at the Erythropoietin (EPO) Receptor Compared with Epoetin Beta: UT-7 and CD34+ cell stimulation assays	Poster	November 18 10:00 – 12:00 Hall C

Author	Abstract Title	Presentation Type	Date & Time of Presentation
NeoRecormon Presentations			
Authors: T. Weinreich, R. Mactier	Haemoglobin Fluctuation In GAIN During 12-Month Follow-Up: Interim Results	Poster	November 18 10:00 – 12:00 Hall C
Authors: R. Mactier, T. Weinreich, R. Ruch	Screening Of Anti-Erythropoietin Antibodies In Haemodialysis Patients With Stable Hb In Europe	Poster	November 18 10:00 – 12:00 Hall C
Author: G. Brillet	Are hemodialysis patients managed according to international guidelines? Results of the French study DiaNE in patients treated with epoetin beta for 1 year.	Poster	November 18 10:00 – 12:00 Hall C
IRIDIEM Presentation			
Authors: P. E. Stevens, N. R. Lameire, G. Schernthaner, S. Thomas , S. Raptis	Can We Follow The Evidence Base? Real World Management Of Patients With CKD And Type 2 Diabetes	Poster	November 18 10:00 – 12:00 Hall C

Roche IR Contacts:

Dr. Karl Mahler
Phone: +41 (0)61 687 85 03
e-mail: karl.mahler@roche.com

Eva Schäfer-Jansen
Phone: +41 (0)61 688 66 36
e-mail: eva.schaefer-jansen@roche.com

Dianne Young
Phone: +41 (0)61 688 93 56
e-mail: dianne.young@roche.com

Dr. Zuzana Dobbie
Phone: +41 (0)61 688 80 27
e-mail: zuzana.dobbie@roche.com

North American investors please contact:

Thomas Kudsk Larsen
Phone: +41 (0)61 687 05 17
Mobile phone: +41 (0)79 829 15 07
e-mail: thomas_kudsk.larsen@roche.com

General inquiries:

International: +41 (0) 61 688 8880
North America: +1 973 562 2233
e-mail: investor.relations@roche.com